Nuvation Bio's Taletrectinib shows promising data in phase 2 trials for ROS1-positive NSCLC. Find out my recommendation on ...

A study from Juniper Research, experts in telecommunications markets, predicts that global revenue from MVNO-in-a-Box ...

Despite this company being a household name in the stock market, our writer would avoid its shares like the plague right now.

With the first two phases of the £1bn Salford scheme complete, developers Scarborough Group International, Metro Holdings, ...